A consensus conference on complex biologics and low molecular weight heparins.
Kalodiki
E
E
Under the auspices of the North American Thrombosis Forum (NATF), the International Union of Angiology (IUA) and the South Asian Society of Atherosclerosisand Thrombosis (SASAT). e.Kalodiki@imperial.ac.uk
Fareed
J
J
Tapson
V F
VF
Hoppensteadt
D A
DA
Sussman
I
I
Carter
C A
CA
Parker
S
S
Harenberg
J
J
Hull
R
R
Rao
G
G
Lovinger
D F
DF
Ried
L D
LD
Kakkar
A
A
Talarico
L
L
Ofuso
F
F
Bussey
H I
HI
Fanikos
J
J
Groce
J B
JB
Skinner
N
N
Ahluwalia
M
M
Iqbal
O
O
Jackson
C M
CM
Jeske
W P
WP
Georges
M
M
Ramacciotti
E
E
Tapson
V F
VF
Van Thiel
D
D
Wahi
R
R
Walenga
J
J
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003257:Consumer Product Safety; D017277:Drug Approval; D005060:Europe; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D009626:Terminology as Topic; D014481:United States; D014486:United States Food and Drug Administration
D000925:Anticoagulants; D001688:Biological Products; D006495:Heparin, Low-Molecular-Weight